simvacol 10 mg comprimido revestido - rezultati iskanja

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

simvacor 10

cipla australia pty ltd - simvastatin, quantity: 10 mg - tablet, film coated - excipient ingredients: ascorbic acid; lactose monohydrate; butylated hydroxyanisole; citric acid monohydrate; pregelatinised maize starch; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; purified talc; hyprolose; iron oxide yellow; iron oxide red; iron oxide black - simvastatin is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin, secondary causes of hypercholesterolaemia (eg poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. simvastatin is indicated in patients at high risk of chd (coronary heart disease) (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

simvador 40mg tablets

dexcel-pharma ltd - simvastatin - oral tablet - 40mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

simvador 80mg tablets

dexcel-pharma ltd - simvastatin - oral tablet - 80mg

Malta - angleščina - Medicines Authority

simvacor

kleva s.a. 189 parnithos avenue, 13671 acharnai, attiki, greece - simvastatin - film-coated tablet - simvastatin 10 mg - lipid modifying agents

Izrael - angleščina - Ministry of Health

simvacor 10

unipharm ltd, israel - simvastatin - film coated tablets - simvastatin 10 mg - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvacor is indicated to: reduce the risk of total mortality by reducing coronary death reduce the risk of non-fatal myocardial infarction reduce the risk for undergoing myocardial revascularization procedures. reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvacor is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvacor therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvacor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hypertri